Prevention of Paclitaxel Neuropathy With Cryotherapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Medical Oncology & Hematology Associates of Northern Virginia
-
Reston, Virginia, United States, 20190
- Medical Oncology & Hematology Associates of Northern Virginia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Women 18 years of age or older
- Histologically or cytological proven diagnosis of breast cancer Stage I- III.
- Must pl an to receive weekly paclitaxel treatment in either the adjuvant or neoadjuvant setting.
- May have received prior treatment including, radiation, surgery chemotherapy hormone and biologics.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- Patient signed informed consent.
- Patient willing and able to comply with scheduled visits and treatment plan.
Exclusion Criteria
- Patient presents with Grade 2 or greater peripheral neuropathy.
- History of Raynaud's Disease.
- Patient presents open or poorly-healing wounds on the hands or feet.
- Patients with cold intolerance.
- Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment contraindicate patient participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cryotherapy
Each patient will receive cryotherapy administered during weekly paclitaxel treatments by Elasto gel™ Hypothermia mitts and slippers.
Patients will wear the mitts and slippers for 15 minutes prior to treatment start, for 60 minutes during treatment, and for 15 minutes following treatment completion, for a total of 90 minutes.
|
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of grade 2 peripheral neuropathies induced by weekly paclitaxel.
Time Frame: From the date of randomization until date of first documented incidence of grade 2 peripheral neuropathy, assessed up to 2 years.
|
From the date of randomization until date of first documented incidence of grade 2 peripheral neuropathy, assessed up to 2 years.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Rate of completion of weekly adjuvant paclitaxel with the use of cryotherapy.
Time Frame: From the date of randomization until date of first documented incidence of grade 2 peripheral neuropathy, assessed up to 2 years.
|
From the date of randomization until date of first documented incidence of grade 2 peripheral neuropathy, assessed up to 2 years.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Mary J Wilkinson, MD, Medical Oncology & Hematology Associates of Northern Virginia
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2014.1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.